Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.81 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034485 | 0.87 | MAPT (0.63) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL245593 | 0.87 | ADORA1 (0.64) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL241556 | 0.84 | MAPT (0.59) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL244863 | 0.84 | ADORA1 (0.61) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL13938147 | 0.84 | ADORA1 (0.62) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL13913748 | 0.83 | ADORA1 (0.74) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL3328078 | 0.82 | MAPT (0.60) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL15286658 | 0.81 | ADORA1 (0.64) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL28185531 | 0.80 | KDM4E (0.73) | MAPTNPSR1RXFP1ADORA1KDM4E | |
| SCHEMBL6462984 | 0.80 | MAPT (0.59) | MAPTNPSR1RXFP1ADORA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| WO-2012000945-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | MAPT 3714/4885NPSR1 3860/4885RXFP1 4386/4885 |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | MAPT 3714/4885NPSR1 3860/4885RXFP1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.